Loading...
•
Dec 31, 2020
Edwards Lifesciences Q4 2020 Earnings Report
Edwards Lifesciences reported fourth quarter results with sales increasing 1 percent and adjusted EPS growing 2 percent.
Key Takeaways
Edwards Lifesciences reported Q4 sales increased 1 percent to $1.2 billion, with underlying sales flat. The company's Q4 EPS was $0.49, and adjusted EPS grew 2 percent to $0.50. The company reiterated its 2021 guidance with sales growth expected in the mid-teens.
Q4 sales increased 1 percent to $1.2 billion; underlying sales flat
Q4 TAVR sales grew 2 percent; underlying sales flat
Q4 EPS was $0.49; adjusted EPS grew 2 percent to $0.50
December investor conference highlighted 2021 and long-term outlook
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Overall, full year 2021 sales guidance for Edwards remains $4.9 to $5.3 billion. Additionally, the company continues to expect full year 2021 adjusted earnings per share of $2.00 to $2.20. For the first quarter of 2021, the company projects total sales to be between $1.1 and $1.2 billion, and adjusted EPS of $0.43 to $0.50.
Positive Outlook
- Full year 2021 sales guidance remains $4.9 to $5.3 billion.
- Full year 2021 adjusted earnings per share expected to be $2.00 to $2.20.
- First quarter of 2021 total sales projected to be between $1.1 and $1.2 billion.
- First quarter 2021 adjusted EPS projected to be $0.43 to $0.50.
- Continuing to invest in innovations to enhance patients’ lives.
Challenges Ahead
- Expect a COVID impact on sales in the start of the year.
- Uncertain impact and timeframe for recovery from the global challenge.
- COVID had a more pronounced impact on the company’s U.S. sales, which declined mid-single digits
- Surgical valve procedures were limited as hospitals experienced an influx of COVID patients
- HemoSphere orders in the U.S. declined as hospitals limited their capital spending
Revenue & Expenses
Visualization of income flow from segment revenue to net income